Site-specific protein-polymer conjugate micelles with dramatically enhanced pharmacology
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Glycosylation and Glycoproteins Research · Monoclonal and Polyclonal Antibodies Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (10)
Show source-provided references
1. Walsh G. Biopharmaceutical benchmarks 2014. Nat Biotechnol, 2014, 32: 992–100010.1038/nbt.3040 ↗
2. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov, 2008, 7: 21–3910.1038/nrd2399 ↗
3. Dusheiko G. Side effects of a interferon in chronic hepatitis C. Hepatology, 1997, 26: 112S–121S10.1002/hep.510260720 ↗
4. Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov, 2003, 2: 214–22110.1038/nrd1033 ↗
5. Liu X, Sun J, Gao W. Site-selective protein modification with polymers for advanced biomedical applications. Biomaterials, 2018, 178: 413–43410.1016/j.biomaterials.2018.04.050 ↗
6. Rajender Reddy K, Modi MW, Pedder S. Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C. Adv Drug Deliver Rev, 2002, 54: 571–58610.1016/S0169-409X(02)00028-5 ↗
7. Talpaz M, Rakhit A, Rittweger K, et al. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res, 2005, 11: 6247–625510.1158/1078-0432.CCR-05-0882 ↗
8. Foser S, Schacher A, Weyer KA, et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon a-2a (PEGASYS). Protein Expres Purif, 2003, 30: 78–8710.1016/S1046-5928(03)00055-X ↗
9. Wang G, Hu J, Gao W. Tuning the molecular size of site-specific interferon-polymer conjugate for optimized antitumor efficacy. Sci China Mater, 2017, 60: 563–57010.1007/s40843-017-9053-y ↗
10. Liu X, Sun M, Sun J, et al. Polymerization induced self-assembly of a site-specific interferon a-block copolymer conjugate into micelles with remarkably enhanced pharmacology. J Am Chem Soc, 2018, 140: 10435–1043810.1021/jacs.8b06013 ↗